Novartis Pursues Acquisitions to Offset Entresto Patent Expiration

Novartis is currently restructuring its drug development pipeline as it prepares for the loss of exclusivity for its heart failure medication, Entresto. Following the spin-off of its generics and biosimilars division, Sandoz, the company is utilizing an aggressive acquisition strategy to replenish its portfolio and secure future growth.

The pharmaceutical firm is prioritizing high-value dealmaking to offset the anticipated revenue impact of Entresto’s patent expiration. By focusing on these strategic investments, Novartis aims to transition its business model toward a more specialized pipeline. This shift follows the company’s decision to separate its Sandoz unit, a move that fundamentally altered the organization’s operational structure and long-term development objectives.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: July 3, 2026

Author

GOAI